J&J Medical Connect
CAPLYTA®

(lumateperone)

+ Save link
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

CAPLYTA® (lumateperone)

Medical Information

CAPLYTA - Dosing - Maximum Dose

Last Updated: 11/13/2025

SUMMARY  

  • Based on clinical trials, the highest recommended daily dosage of CAPLYTA is 42 mg.1 
  • Johnson and Johnson does not recommend the use of CAPLYTA in a manner that is inconsistent with the prescribing information.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) conducted on 13 October 2025 did not identify any relevant citations pertaining to this topic.

 

References

Show
1 CAPLYTA (lumateperone) [Prescribing Information]. Bedminster, NJ: Intra-Cellular Therapies, Inc; https://www.intracellulartherapies.com/docs/caplyta_pi.pdf